EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD.

1045Background: In the Phase III OlympiAD study, pts with HER2-negative mBC and a gBRCAm who received olaparib vs TPC showed statistically significant and clinically meaningful benefit in progression-free survival (NCT02000622; Robson et al. NEJM 2017). Global health status/quality of life also favored olaparib. This analysis reports the impact of treatment on symptoms using the QLQ-C30 questionnaire. Methods: Pts were randomized (open label) to olaparib tablet monotherapy or single-agent TPC (capecitabine, vinorelbine or eribulin). QLQ-C30, completed by patients at baseline and every 6 weeks until disease progression, evaluated three multi-item symptom scales and five single items (common cancer symptoms). Symptoms were scored on a 0 to 100 scale (higher scores indicated worse symptoms). Statistical analysis included clinically meaningful improvement (reduction in score of ≥10 points) and adjusted mean change from baseline scores. Results: Overall questionnaire compliance rates were 93.2% for olaparib an...